188 related articles for article (PubMed ID: 27581662)
61. The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.
Verret B; Sourisseau T; Stefanovska B; Mosele F; Tran-Dien A; André F
Cancer Res; 2020 Aug; 80(15):3062-3069. PubMed ID: 32245795
[TBL] [Abstract][Full Text] [Related]
62. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients.
Hauch S; Zimmermann S; Lankiewicz S; Zieglschmid V; Böcher O; Albert WH
Anticancer Res; 2007; 27(3A):1337-41. PubMed ID: 17593628
[TBL] [Abstract][Full Text] [Related]
63. Intratumor heterogeneity: nature and biological significance.
Gerashchenko TS; Denisov EV; Litviakov NV; Zavyalova MV; Vtorushin SV; Tsyganov MM; Perelmuter VM; Cherdyntseva NV
Biochemistry (Mosc); 2013 Nov; 78(11):1201-15. PubMed ID: 24460935
[TBL] [Abstract][Full Text] [Related]
64. Well-differentiated neuroendocrine tumour of the breast showing peculiar endovascular spread.
Kawasaki T; Bussolati G; Marchiò C; Castellano I; Daniele L; Molinaro L; Hinata M; Furuya K; Nakagomi H; Oyama T; Tsunoda H; Sugai T; Katoh R; Sapino A
Histopathology; 2014 Mar; 64(4):597-600. PubMed ID: 24215290
[No Abstract] [Full Text] [Related]
65. [Circulating tumor cells: cornerstone of personalized medicine].
Rafii A; Vidal F; Rathat G; Alix-Panabières C
J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):640-8. PubMed ID: 25017712
[TBL] [Abstract][Full Text] [Related]
66. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine.
Roukos DH
Drug Discov Today; 2017 Aug; 22(8):1148-1164. PubMed ID: 28400153
[TBL] [Abstract][Full Text] [Related]
67. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Gerratana L; Davis AA; Shah AN; Lin C; Corvaja C; Cristofanilli M
Curr Treat Options Oncol; 2019 Jun; 20(8):68. PubMed ID: 31256282
[TBL] [Abstract][Full Text] [Related]
68. Clinical implications of the detection of circulating tumor cells in breast cancer patients.
Banys M; Hartkopf AD; Krawczyk N; Becker S; Fehm T
Biomark Med; 2012 Feb; 6(1):109-18. PubMed ID: 22296204
[TBL] [Abstract][Full Text] [Related]
69. Heterogeneity of breast cancer: etiology and clinical relevance.
Almendro V; Fuster G
Clin Transl Oncol; 2011 Nov; 13(11):767-73. PubMed ID: 22082639
[TBL] [Abstract][Full Text] [Related]
70. Precision medicine in breast cancer: reality or utopia?
Bettaieb A; Paul C; Plenchette S; Shan J; Chouchane L; Ghiringhelli F
J Transl Med; 2017 Jun; 15(1):139. PubMed ID: 28623955
[TBL] [Abstract][Full Text] [Related]
71. Circulating cancer cells in division in an early breast cancer patient.
Serrano MJ; Nadal R; Lorente JA; Salido M; Rodríguez R; Rodríguez M; Macià M; Sánchez-Rovira P; Corominas JM; González L; Vera L; Albanell J; Solé F
Ann Oncol; 2011 Sep; 22(9):2150-2151. PubMed ID: 21743104
[No Abstract] [Full Text] [Related]
72. Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era.
Yan J; Liu Z; Du S; Li J; Ma L; Li L
Methods Mol Biol; 2020; 2204():53-61. PubMed ID: 32710314
[TBL] [Abstract][Full Text] [Related]
73. Combinatorial drug therapy for cancer in the post-genomic era.
Al-Lazikani B; Banerji U; Workman P
Nat Biotechnol; 2012 Jul; 30(7):679-92. PubMed ID: 22781697
[TBL] [Abstract][Full Text] [Related]
74. Circulating tumor cell count: A reliable biomarker for treatment selection in metastatic breast cancer.
Li B; Zheng Y
Thorac Cancer; 2022 Jan; 13(2):265-266. PubMed ID: 34873852
[No Abstract] [Full Text] [Related]
75. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients.
Reyal F; Valet F; de Cremoux P; Mathiot C; Decraene C; Asselain B; Brain E; Delaloge S; Giacchetti S; Marty M; Pierga JY; Bidard FC
Ann Oncol; 2011 Jun; 22(6):1458-1459. PubMed ID: 21525400
[No Abstract] [Full Text] [Related]
76. Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation.
Pongor L; Harami-Papp H; Méhes E; Czirók A; Győrffy B
Sci Rep; 2017 Aug; 7(1):7358. PubMed ID: 28779157
[TBL] [Abstract][Full Text] [Related]
77. Circulating tumour cells in early breast cancer.
De Mattos-Arruda L; Tabernero J; Seoane J; Cortes J
Lancet Oncol; 2012 Sep; 13(9):e370; author reply e370. PubMed ID: 22935235
[No Abstract] [Full Text] [Related]
78. Circulating tumour cells in early breast cancer.
Nair VS; Keu KV; Kuhn P; Gambhir SS
Lancet Oncol; 2012 Sep; 13(9):e370-1; author reply e371. PubMed ID: 22935234
[No Abstract] [Full Text] [Related]
79. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.
Hiley C; de Bruin EC; McGranahan N; Swanton C
Genome Biol; 2014 Aug; 15(8):453. PubMed ID: 25222836
[TBL] [Abstract][Full Text] [Related]
80. Intratumor heterogeneity: predicting and preventing therapeutic resistance.
Ziogas DE; Zerdes I; Lykoudis EG; Glantzounis G; Roukos DH
Biomark Med; 2016 Jul; 10(7):681-4. PubMed ID: 27338870
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
